Objective: Patients who received pituitary-derived growth hormone (GH) are at excess risk of mortality from Creutzfeldt-Jakob disease. We investigated whether they were at increased risk of death from other conditions, particularly preventable conditions.
Study Design: A cohort (N=6107) from known US pituitary-derived GH recipients (treated 1963-1985) was studied. Deaths were identified by reports from physicians and parents and the National Death Index. Rates were compared with the expected rates for the US population standardized for race, age, and sex.
Results: There were 433 deaths versus 114 expected (relative risk [RR], 3.8; 95% confidence interval [CI], 3.4-4.2; P<.0001) from 1963 through 1996. Risk was increased in subjects with GH deficiency caused by any tumor (RR, 10.4; 95% CI, 9.1-12.0; P<.0001). Surprisingly, subjects with hypoglycemia treated within the first 6 months of life were at extremely high risk (RR, 18.3; 95% CI, 9.2-32.8; P<.0001), as were all subjects with adrenal insufficiency (RR, 7.1; 95% CI, 6.2-8.2; P<.0001). A quarter of all deaths were sudden and unexpected. Of the 26 cases of Creutzfeldt-Jakob disease, four cases have died since 2000.
Conclusions: The death rate in pituitary-derived GH recipients was almost four times the expected rate. Replacing pituitary-derived GH with recombinant GH has eliminated only the risk of Creutzfeldt-Jakob disease. Hypoglycemia and adrenal insufficiency accounted for far more mortality than Creutzfeldt-Jakob disease. The large number of potentially preventable deaths in patients with adrenal insufficiency and hypoglycemia underscores the importance of early intervention when infection occurs in patients with adrenal insufficiency, and aggressive treatment of panhypopituitarism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpeds.2003.12.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Growth hormone (GH) is a pituitary derived endocrine hormone required for normal post-natal growth and development. Hypo or hypersecretion of endocrine GH results in two pathologic conditions, namely GH deficiency (GHD) and acromegaly. Additionally, GH is also produced in non-pituitary and tumoral tissues where it acts rather as a cellular growth factor with an autocrine/paracrine mode of action.
View Article and Find Full Text PDFRecombinant GH Therapy: Expected Results, Modalities and Monitoring in Children.
Front Horm Res
November 2024
Endocrinology and Diabetes Unit, IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.
Article Synopsis
- - Growth hormone treatment has evolved from using pituitary-derived GH for specific cases of GH deficiency to recombinant human GH (rhGH), which is now approved for various disorders beyond just GH deficiency.
- - RhGH significantly helps improve short stature in GH-deficient patients and has positive effects on metabolic and bone health, with long-term safety studies showing encouraging results, particularly for those with isolated GHD.
- - New long-acting rhGH formulations are being developed to enhance adherence to treatment and lessen the burden on patients, while ongoing surveillance is needed for safety in higher doses or other clinical conditions.
Induction of apoptosis by oridonin in nonfunctioning pituitary adenoma cells.
Drug Dev Res
September 2024
Pituitary Tumor Center, Department of Neurosurgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Nonfunctioning pituitary adenoma (NFPA) is one of the major subtypes of pituitary adenomas (PA) and its primary treatment is surgical resection. However, normal surgery fails to remove lesions completely and there remains in lack of frontline treatment, so the development of new drugs for NFPA is no doubt urgent. Oridonin (ORI) has been reported to have antitumor effects on a variety of tumors, but whether it could exhibit the same effect on NFPA requires to be further investigated.
View Article and Find Full Text PDFInsufficient evidence for an association between iatrogenic Alzheimer's disease and cadaveric pituitary-derived growth hormone.
Alzheimers Dement
October 2024
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
A Nature Medicine paper published in January 2024 describes eight cases of iatrogenic Alzheimer's disease in individuals who received cadaveric pituitary-derived human growth hormone. The paper's conclusions argue for the transmissibility of Alzheimer's disease, which, if true, would create a significant public health crisis. For example, neurosurgical practices would require substantial revision, and many individuals who have undergone neurosurgical procedures would now be at considerable risk of Alzheimer's disease.
View Article and Find Full Text PDFPituitary-derived small extracellular vesicles promote liver repair by its cargo miR-143-3p.
Sci Rep
July 2024
College of Animal Science, Guangdong Province Key Laboratory of Animal Nutritional Regulation, National Engineering Research Center for Breeding Swine Industry, State Key Laboratory of Livestock and Poultry Breeding, South China Agricultural University, Guangzhou, 510642, Guangdong, China.
The small Extracellular vesicles (sEV) has been recognized to be significant for intercellular communication due to their ability to transfer important cellular cargoes like miRNAs through circulation. The pituitary gland has not been clearly known about the role of its secreted sEV under normal physiological conditions. And Liver disease is a global public health burden.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!